Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
11 10월 2023 - 8:00PM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical
company developing and delivering novel therapies for the
management of central nervous system (CNS) disorders, today
announced that Susan Mahony, PhD, has been appointed to Axsome’s
board of directors, effective immediately.
Dr. Mahony most recently served on the board of
directors of Horizon Therapeutics from 2019 until its acquisition
by Amgen in October 2023. She was formerly Senior Vice President of
Eli Lilly and Company and President of Lilly Oncology, where under
her leadership, the business unit evolved from one to five marketed
medicines. At Lilly, she held leadership positions and led
organizations in Europe, the United States, Canada, Japan, and
China. Prior to Lilly, Dr. Mahony led commercial activities for
Bristol Myers Squibb’s cardiovascular business and worked in sales
and marketing at Amgen and Schering Plough.
“We are pleased to welcome Dr. Mahony, who has
extensive leadership experience in global drug development and
commercialization, to our board of directors,” said Herriot
Tabuteau, MD, Chief Executive Officer of Axsome. “Dr. Mahony is an
excellent complement to the rest of our board, expanding its
perspectives and expertise, as we work to create significant value
for shareholders. Dr. Mahony’s lifetime commitment to helping
patients with serious conditions will advance our mission of
developing and delivering innovative treatment options for critical
areas of unmet patient need in the CNS space.”
Dr. Mahony added, “I am excited to join the
Axsome board and work with the other directors and members of the
leadership team to help advance the Company’s commercial portfolio
and robust product candidate pipeline. Axsome has an enviable track
record of focused, productive, and efficient drug development. With
two differentiated commercial products in early launch phases, and
the potential to have up to six marketed products by 2025, now is a
time of potentially important inflection for the Company. I look
forward to contributing to Axsome’s continued transformation into a
premier CNS-focused biopharmaceutical company.”
Dr. Mahony earned her Bachelor of Science in
Pharmacy, and her Doctor of Philosophy in Oncology from the
University of Aston, UK. She also earned her Master of Business
Administration from the London School of Business. Dr. Mahony
served on the board of directors of Vifor Pharma from 2019 until
its acquisition by CSL Limited in 2022. Dr. Mahony currently serves
on the board of directors of Zymeworks Inc. and Assembly
Biosciences. Dr. Mahony also serves on the board of directors of
the Chordoma Foundation, a nonprofit dedicated to improving the
lives of people affected by chordoma.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical
company developing and delivering novel therapies for central
nervous system (CNS) conditions that have limited treatment
options. Through development of therapeutic options with novel
mechanisms of action, we are transforming the approach to treating
CNS conditions. At Axsome, we are committed to developing products
that meaningfully improve the lives of patients and provide new
therapeutic options for physicians. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
continued commercial success of our Sunosi® and Auvelity® products
and the success of our efforts to obtain any additional
indication(s) with respect to solriamfetol and/or AXS-05; the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected revenues or expenses), futility
analyses and receipt of interim results, which are not necessarily
indicative of the final results of our ongoing clinical trials,
and/or data readouts, and the number or type of studies or nature
of results necessary to support the filing of a new drug
application (“NDA”) for any of our current product candidates; our
ability to fund additional clinical trials to continue the
advancement of our product candidates; the timing of and our
ability to obtain and maintain U.S. Food and Drug Administration
(“FDA”) or other regulatory authority approval of, or other action
with respect to, our product candidates, including statements
regarding the timing of any NDA submission; whether issues
identified by FDA in the complete response letter may impact the
potential approvability of the Company’s NDA for AXS-07 for the
acute treatment of migraine in adults with or without aura,
pursuant to our special protocol assessment for the MOMENTUM
clinical trial; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s products and product
candidates, if approved; the Company’s anticipated capital
requirements, including the amount of capital required for the
continued commercialization of Sunosi and Auvelity and for the
Company’s commercial launch of its other product candidates, if
approved, and the potential impact on the Company’s anticipated
cash runway; unforeseen circumstances or other disruptions to
normal business operations arising from or related to COVID-19; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contacts:
Investors:Mark JacobsonChief Operating OfficerAxsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 212-332-3243Email: mjacobson@axsome.com
www.axsome.com
Media:
Darren OplandDirector, Corporate CommunicationsAxsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 929-837-1065Email: dopland@axsome.com www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Axsome Therapeutics (NASDAQ:AXSM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024